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The objectives of the present study were to determine the effects of multiple targeted interventions on the
level of use of quinolones and the observed rates of resistance to quinolones in Escherichia coli isolates from
hospitalized patients. A bundle consisting of four interventions to improve the use of quinolones was imple-
mented. The outcome was measured from the monthly levels of use of intravenous (i.v.) and oral quinolones
and the susceptibility patterns for E. coli isolates from hospitalized patients. Statistical analyses were per-
formed using segmented regression analysis and segmented Poisson regression models. Before the bundle was
implemented, the annual use of quinolones was 2.7 defined daily doses (DDDs)/100 patient days. After the
interventions, in 2007, this was reduced to 1.7 DDDs/100 patient days. The first intervention, a switch from i.v.
to oral medication, was associated with a stepwise reduction in i.v. quinolone use of 71 prescribed daily doses
(PDDs) per month (95% confidence interval [CI]  47 to 95 PDDs/month, P < 0.001). Intervention 2,
introduction of a new antibiotic guideline and education program, was associated with a stepwise reduction in
the overall use of quinolones (reduction, 107 PDDs/month [95% CI  58 to 156 PDDs/month). Before the
interventions the quinolone resistance rate was increasing, on average, by 4.6% (95% CI  2.6 to 6.1%) per
year. This increase leveled off, which was associated with intervention 2 and intervention 4, active monitoring
of prescriptions and feedback. Trends in resistance to other antimicrobial agents did not change. This study
showed that the hospital-wide use of quinolones can be significantly reduced by an active policy consisting of
multiple interventions. There was also a stepwise reduction in the rate of quinolone resistance associated with
the bundle of interventions.
The use of antimicrobial agents and the rates of antimicro-
bial resistance vary significantly between countries (8, 9, 16,
27). A substantial proportion of the antimicrobial use is con-
sidered inappropriate (30). Apart from the unnecessary costs
and potential harm to the patient, inappropriate use can lead
to increased selection for and transmission of resistant micro-
organisms. A recent survey in the Amphia Hospital, Breda,
Netherlands, showed that approximately 40% of all antibiotic
prescriptions were considered inappropriate (e.g., unneces-
sary, incorrect choice, or incorrect dosage). The only indepen-
dent variable associated with inappropriate use was the use of
quinolones (30). In many cases the use of quinolones was
incorrect because there was no indication for antimicrobial
therapy, alternative antimicrobials should have been used (on
the basis of hospital, national, and international guidelines), or
quinolones were used intravenously (i.v.) where oral forms
would suffice. The use of quinolones promotes the spread of
antibiotic resistance genes by activating an SOS response, as
reported by Beaber et al. (1). This means that the use of
quinolones could account for the rapid manner in which resis-
tance genes are disseminating. We therefore performed an
intervention study to correct the use of quinolones in hospi-
talized patients and to determine its effect on the associated
costs and the rate of resistance observed in Escherichia coli.
MATERIALS AND METHODS
The study was designed as a prospective interrupted time series study consist-
ing of four interventions. The study was performed in the Amphia Hospital,
which is a 1,370-bed teaching hospital that includes most medical specialties. The
outpatient clinic, the intensive care unit (ICU), and the psychiatry ward were
excluded from the interventions. However, these departments were included in
the analysis for observed resistance. In 2006, there were 41,712 admissions and
279,403 bed days.
Interventions. During the study period, four interventions involving the use of
ciprofloxacin (CIP), the only fluoroquinolone used in the Amphia Hospital were
carried out. The interventions were coordinated by a single dedicated project
manager. The project manager coordinated all activities of coworkers involved in
the project, i.e., consultant microbiologists, pharmacists, pharmacy assistants,
and medical specialists.
(i) Intervention 1. Intervention 1 consisted of a switch from i.v. to oral med-
ication (Switch project) (from 1 January 2006 until 31 December 2007). The
guideline for an early switch was developed primarily by the hospital antibiotic
policy committee and was subsequently approved by the physicians in the hos-
pital. The criteria for a switch from i.v. to oral medication were as follows: first,
the patient had to be able to take medication orally (p.o.); second, the patient
had to be hemodynamically stable (pulse, 100 beats/min, systolic blood pres-
sure, 100 mmHg); and third, no switch was allowed if the patient was on
parenteral nutrition (4, 5, 10, 24). If a switch was performed, the following rules
were applied: a dosage of 200 mg twice a day (b.i.d.) i.v. was switched to 500 mg
b.i.d. p.o., and one of 400 mg b.i.d. i.v. was switched to 750 mg b.i.d. p.o. The use
* Corresponding author. Mailing address: Laboratory for Microbi-
ology and Infection Control, Amphia Hospital, P.O. Box 90158, 4800
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of aluminum- or magnesium-containing antacids, sucralfate, and calcium, bis-
muth, zinc, and iron salts disturbs the uptake of CIP (18). In those cases, CIP oral
medication was administrated more than 2 h before or greater than 4 h after they
took another medication(s). From Monday through Friday, all patients with CIP
i.v. prescriptions were identified in the pharmacy department information system
and checked against the hospital antibiotic policy by a pharmacy assistant. If the
patient was considered suitable for a switch, the attending physician was con-
tacted by the pharmacy assistant and a switch was recommended. If the patient
was considered potentially suitable but no definite conclusions could be made,
the consultant microbiologist was contacted by the pharmacy assistant for advice.
If the consultant microbiologist considered the patient suitable for a switch, that
individual contacted the attending physician and a switch was recommended. If
the patient was considered not suitable for a switch, the i.v. therapy was contin-
ued.
(ii) Intervention 2. Intervention 2 consisted of a new antimicrobial guideline
for antibiotic use and educational program. On 15 May 2006, a new guideline for
antibiotic use was issued in Amphia Hospital. This guideline was developed by
the hospital antibiotic policy committee and was subsequently approved by the
physicians. The guideline was based on national and international recommen-
dations and adapted to the susceptibility patterns of local pathogens (19). The
guideline recommended that empirical use of CIP would be reserved for patients
with severe gastroenteritis, prostatitis, or diabetic foot ulcers. In other cases the
use of CIP should be based on microbiological diagnostic results. The guideline
was sent to all interns, residents, and physicians in a pocket-sized brochure and
was made available on the intranet of Amphia Hospital. In June 2006, residents
attended group education sessions informing them about the prescription of
antimicrobial agents for clinical patients. Restrictive use of CIP was highlighted.
(iii) Intervention 3. Intervention 3 consisted of a restriction note on laboratory
reports. In November 2006, a comment on the use of CIP was added to all
microbiology results reports: “According to the hospital guideline on antimicro-
bial treatment, ciprofloxacin is considered a restricted antibiotic which should be
prescribed on strict indications only.” Furthermore, a letter about the increasing
rates of resistance to CIP in Amphia Hospital was sent to all physicians and
requested that they follow the local guidelines for antimicrobial therapy.
(iv) Intervention 4. Intervention 4 consisted of active monitoring of prescrip-
tions and feedback. On 1 January 2007, the fourth intervention was initiated.
This consisted of active monitoring of CIP prescriptions and the provision of
feedback to the prescriber. The hospital’s computerized pharmacy records were
used to retrieve all orders for CIP prescriptions on a daily basis. Initial screening
for the appropriateness of the prescriptions was performed by the project coor-
dinator, according to the local antibiotic prescription guidelines. If the prescrip-
tions did not meet the criteria specified in the guideline, the consultant micro-
biologist would contact the prescribing intern/resident to discuss the
appropriateness of CIP use. The recommendations were registered on a stan-
dardized form, and follow-up on the use of the recommendations was checked by
the pharmacy assistant.
Outcome measures. The monthly use of CIP i.v. and orally (in grams) was
calculated on the basis of the pharmacy department data. Treatment duration
was calculated as the difference (in days) between the prescription start and stop
dates. If the dosage or method of administration (i.v. or oral) of CIP was changed
during therapy, it was assumed that the change had occurred at the beginning of
the first day that the patient received the new preparation. The use of CIP (i.v.,
oral, and total) was translated into prescribed daily doses (PDDs), using 0.8 g as
1 PDD for i.v. CIP and 1.0 g as 1 PDD for oral CIP. The CIP use data were
evaluated monthly by a team, including a hospital pharmacist, pharmacy assis-
tant, consultant microbiologist, and the project coordinator. The annual total
antibiotic consumption and CIP consumption were translated to PDDs and
defined daily doses (DDDs), according to the 2005 Anatomical Therapeutic
Chemical Classification System (ATC)/DDD index from the WHO Collaborat-
ing Centre for Drug Statistics Methodology (33). Consumption data from the
outpatient department were excluded from the analysis.
The susceptibility patterns, including susceptibility to CIP, cefuroxime
(CFRX), ceftazidime (CFTZ), trimethoprim-sulfamethoxazole (TMP-SMZ),
and tobramycin (TOBR), of the E. coli isolates from hospitalized patients,
recovered after more than 48 h after admission, were analyzed. The susceptibility
patterns were obtained from the laboratory information system from 1 January
2004 to 31 December 2007. Antimicrobial susceptibility testing was performed
using an automated system (Vitek bioMe´rieux). Interpretation of the antimicro-
bial susceptibility test results was based on guidelines from the Clinical and
Laboratory Standards Institute (CLSI) (3). Repeat isolates from a patient after
recovery of the initial isolate were excluded from analysis, unless there was a
major difference in the susceptibility patterns. A major difference was defined
when at least one change from susceptible to resistance was observed. Analyses
were performed by considering intermediate susceptibility to be susceptible.
Targets and funding. At the initiation of the interventions, the following
targets were defined: (i) a 50% reduction of i.v. CIP prescriptions and (ii) a 30%
reduction of the absolute amount of CIP use.
On the basis of these assumptions and the anticipated cost savings, the hospital
management funded the project by providing financing for a study coordinator
(12 h per week) and a pharmacy assistant (18 h per week) during 2006 and 2007.
Data analysis. The privacy of the patients was maintained by coding all data,
according to the requirements of the privacy regulation of the Amphia Hospital.
Statistical analyses of the CIP use data were performed using segmented regres-
sion analysis to allow both stepwise changes and changes in trends, accounting
for the combined effects of the interventions on both (20). Bayesian model
averaging (BMA) was used to account for model uncertainty by selecting the
most likely models (those with the highest posterior probability) and to obtain
parameter estimates averaged over the most probable models (by weighting the
models by posterior probability) (12). Statistical analyses of the trend in CIP
resistance in E. coli isolates was performed using segmented Poisson regression
models with log-link functions, adjusting for the total number of E. coli isolates
tested for resistance. The models considered allowed both stepwise changes and
log-linear changes in trends, again allowing the cumulative effects of the different
interventions and accounting for model uncertainty using BMA (12). In all cases,
equal prior probabilities were assigned to possible models and estimated param-
eters were obtained by averaging over all models that were at least 1/20 as likely
as the most likely model (though we report only the three most likely models, in
addition to the full model and the model-averaged result). Confidence intervals
(CIs) were calculated using at least 100 bootstrap replicates. Analysis was per-
formed in the R (version 2.9) and Stata (release 10) programs (22, 26).
RESULTS
Use of CIP i.v. During the first 12 months, before the inter-
ventions were implemented, the monthly use of CIP was stable
(mean, 561 PDDs; range, 333 to 634). During the year 2006,
181 patients on CIP i.v. were considered for a switch to oral
medication. According to the protocol, 136 (76%) were suit-
able and a switch was performed for 92 (51%) patients. Di-
rectly after the start of the intervention in January 2006, the
level of i.v. CIP use was reduced (Fig. 1). In the segmented
FIG. 1. Monthly use of intravenous ciprofloxacin from 2005
through 2007, in PDDs. Values predicted by the best-segmented re-
gression model are shown by the solid line. Broken lines show the 95%
confidence intervals.
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regression analysis of the CIP i.v. data, the most reliable esti-
mate of the combined effects due to the interventions (the
model-averaged results) revealed strong evidence that inter-
vention 1 was associated with a large sudden fall in i.v. CIP use,
with a probability of 1 of a stepwise change being due to this
intervention. In contrast, the full model (incorporating cumu-
lative stepwise changes in levels and changes in trends associ-
ated with each intervention) suggested that there was no evi-
dence that any of the four interventions had any impact (Table
1). However, because of multicolinearity, these full model pa-
rameter estimates were unstable and therefore unreliable.
There was considerable model uncertainty (Table 1, footnote
a), with the three best-fitting models all having similar poste-
rior probabilities, close to 10%. This model uncertainty is ac-
counted for in the model-averaged results. In the single most
likely model (model 1), the level of CIP i.v. use significantly
decreased after intervention 4, but accounting for model un-
certainty suggested that the true effect was smaller and consis-
tent with chance. Only the effect of intervention 1 was robust to
model uncertainty. The annual use of CIP i.v. in the hospital
decreased from 1,544 PDDs in 2005 to 696 PDDs in 2006 (a
55% reduction) and 384 PDDs in 2007 (a 75% reduction com-
pared to the level for 2005).
Total use of CIP. The interventions targeted at the overall
reduction of the use of CIP (i.v. and oral) started with inter-
vention 2 in May/June 2006. Using segmented regression anal-
ysis, 19 models were selected. In this case the full model, the
single best model (model 1), and the model-averaged results all
agreed and showed strong evidence of a step reduction in CIP
use associated with intervention 2 (Fig. 2; Table 2). The best
estimate of this (the model-averaged result; Table 2) is a re-
duction of 131 PDDs/month (95% CI  34 to 228 PDDs/
month). The annual total use of CIP in the hospital, excluding
the ICU, decreased from 6,530 PDDs in 2005 to 5,681 PDDs in
2006 (a 13% reduction) and to 3,670 PDDs in 2007 (a 42%
reduction compared to the annual use in 2005). The annual
hospital use of CIP decreased from 2.7 DDDs/100 patient days
in 2005 to 1.7 DDDs/100 patient days in 2007 (Fig. 3). The total
antimicrobial use in the hospital increased in the years before
the intervention. This increase leveled off in 2006 and 2007, as
shown in Fig. 3. No increase in the rates of use of specific
groups of antimicrobial agents was observed, and no new an-
timicrobials were used.
Resistance rates in E. coli. Before the start of the interven-
tions, the CIP resistance rate in E. coli was increasing by about
5% per year (Fig. 4; Table 3). In the best-fitting Poisson model
for the resistance data, a significant stepwise decrease was
found to be associated with interventions 2 and 4. However,
there was substantial uncertainty in the model choice (the most
likely model had a posterior probability of only 0.11), and after
accounting for this in the model-averaged results, there was no
conclusive evidence in support of any particular intervention.
TABLE 1. Segmented regression results for the ciprofloxacin intravenous dataa
Intervention or
parameter
Model-averaged
coefficientb
(SD)
Probability
of an
intervention
effectc
Full model Model 1 Model 2 Model 3
Coefficient
(95% CI) P
Coefficient
(95% CI) P
Coefficient
(95% CI) P
Coefficient
(95% CI) P
Intervention 1 67.9 (17.0) 1 61.9 (138.6, 14.9) 0.11 70.7 (94.6, 46.7) 0.001 68.8 (94.1, 43.5) 0.001 61.4 (91.7, 31.2) 0.001
Intervention 2 1.3 (6.6) 0.07 30.8 (115.5, 54.0) 0.46
Intervention 3 4.3 (11.5) 0.20 53.1 (206.9, 100.7) 0.48 25.4 (49.9, 0.98) 0.04
Intervention 4 7.0 (14.6) 0.30 24.2 (100.5, 52.1) 0.52 26.0 (50.0, 2.0) 0.035
Trend prior to
intervention
0.1 (0.5) 0.09 0.78 (4.6, 6.2) 0.77
Change in
trend after
intervention:
1 0.4 (2.0) 0.16 3.2 (24.4, 18.1) 0.76 1.8 (3.5, 0.03) 0.05
2 0.02 (1.9) 0.13 11.6 (17.5, 40.6) 0.42
3 0.2 (0.9) 0.12 9.4 (84.8, 103.5) 0.84
4 0.2 (0.9) 0.10 18.8 (110.8, 73.3) 0.68
a The results of the model-averaged estimates, full model, and three best-fitting models selected by Bayesian model averaging are shown. The posterior model
probabilities were 0.01, 0.13, 0.11, and 0.10 for the full model and models 1 to 3, respectively.
b Expected value of the coefficient obtained by Bayesian model averaging, combining results from multiple models, weighted according to model probability (see
Materials and Methods).
c The probability that the coefficient is not zero in the Bayesian model averaging results.
FIG. 2. Monthly use of ciprofloxacin (intravenous and oral) from
2005 through 2007, in PDDs. Values predicted by the best-segmented
regression model are shown by the solid line. Broken lines show the
95% confidence intervals.
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There was, however, evidence that at least one of interventions
2, 3, and 4 was associated with the observed stepwise reduction
in resistance; all the best-fitting models included reductions
associated with at least one of these. There was little evidence
for the efficacy of intervention 1. Very strong evidence was
found for an initial increasing trend and little support for
models that included a decreasing trend term associated with
the interventions. Thus, interventions 2 to 4 may have caused
a stepwise reduction in resistance but were unable to reverse
the increasing trend.
The rates of resistance to CFRX, CFTZ, TMP-SMZ, and
TOBR were studied. There was strong evidence for an increas-
ing trend in the rates of resistance to CRFX and CFTZ. None
of the interventions had any effect on these resistance rates.
The rates of resistance to TMP-SMZ and TOBR showed no
trend up or down, and the interventions did not affect the
observed resistance rates.
Costs and savings. Considering only the price of the agent,
switching patients from i.v. CIP to oral CIP saved the hospital
about €114,000 over 2 years, on the basis of the CIP price in
2005. The overall savings were higher than this, but the addi-
tional savings were not calculated because reliable data were
not available. The annual cost of the program was approxi-
mately €32,000, based on the salaries of the study coordinator
and the pharmacy assistant.
DISCUSSION
This study shows that implementation of a bundle of inter-
ventions targeted at the improved use of CIP was associated
with a significant decrease in the level of use of i.v. CIP as well
as a decrease in the overall level of use of CIP. The level of i.v.
use of CIP decreased immediately after the first intervention
(the Switch project). The Switch project improved the quality
of care and resulted in important savings, which were sufficient
to fund the entire project. The switch from the i.v. to the oral
route had several other advantages, which include decreasing
TABLE 2. Segmented regression results for the total ciprofloxacin dataa
Intervention or
parameter
Model-averaged
coefficientb
(SD)
Probability
of an
intervention
effectc
Full model Model 1 Model 2 Model 3
Coefficient
(95% CI) P
Coefficient
(95% CI) P
Coefficient
(95% CI) P
Coefficient
(95% CI) P
Intervention 1 0.4 (8.7) 0.05 9.3 (196.7, 178.1) 0.92
Intervention 2 130.8 (49.4) 1 249.0 (455.9,42.2) 0.02 107.0 (157.6,56.4) 0.001 136.2 (204.2,68.3) 0.001 128.7 (184.2,73.3) 0.001
Intervention 3 4.9 (19.5) 0.12 86.8 (462.2, 288.7) 0.64 39.6 (30.0, 109.3) 0.26
Intervention 4 4.7 (19.5) 0.11 18.5 (167.8, 204.8) 0.84 34.3 (28.3, 97.0) 0.27
Trend prior to
intervention
0.004 (0.9) 0.07 5.2 (18.5, 8.0) 0.43
Change in
trend after
intervention:
1 0.8 (3.3) 0.13 20.3 (31.6, 72.2) 0.43
2 1.4 (6.3) 0.13 10.7 (60.2, 81.7) 0.76
3 0.5 (8.3) 0.16 15.2 (214.8, 245.1) 0.89
4 1.5 (7.7) 0.16 44.6 (269.4, 180.2) 0.69
a The results of the model-averaged estimates, the full model, and three best-fitting models selected by BMA are shown. The posterior model probabilities were
0.01, 0.29, 0.09, and 0.08 for the full model and models 1 to 3, respectively.
b The expected value of the coefficient obtained by Bayesian model averaging, combining results from multiple models, weighted according to model probability (see
Materials and Methods).
c The probability that the coefficient is not zero in the Bayesian model averaging results.
FIG. 3. Annual ciprofloxacin use and overall use.
FIG. 4. Observed rates of resistance to ciprofloxacin by E. coli
isolates from hospitalized patients from 2004 through 2007. Values
predicted by the best-segmented regression model are shown by the
solid line. Broken lines show the 95% confidence intervals.
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the risk of complications from i.v. catheters, increasing the
patient’s comfort and mobility, and discharging the patient
from the hospital earlier because the patient no longer had an
i.v. catheter (5, 17).
The overall level of use of CIP was reduced, which was most
likely caused by intervention 2, which comprised the introduc-
tion of a new guideline and an educational program. We did
not detect an additional effect of interventions 3 and 4, but we
cannot determine if these interventions influenced the sustain-
ability of the effect. Therefore, we conclude that the combina-
tion of interventions reduced the overall level of use of CIP
and that intervention 2 was an essential part of the bundle.
Intervention 2 was relatively simple and required limited re-
sources. Van Hees et al. described a similar significant reduc-
tion due to educational interventions targeted at CIP use in a
hospital with a low level of CIP use (5.7 DDDs/100 patient days
in 2004) (29). However, those CIP use data were difficult to
compare with our findings because the antimicrobial use was
expressed in the number of prescriptions per 1,000 admissions
and only a limited number of wards was included in the inter-
vention program. These studies show the effect of having an-
timicrobial guidelines and implementing them locally by using
educational sessions on use of the antimicrobial.
To put these findings into perspective, it is important to
understand that the current study was performed in a setting
with a relatively low level of quinolone use compared with that
at most Dutch hospitals (27). The average level of Dutch hos-
pital use of quinolones in 2005 was 7.4 DDDs/100 patient days
(6). This is nearly three times higher than the level in our
hospital in 2005 (Fig. 3). During the study period, the use of
CIP declined further to 1.7 DDDs/100 patient days in 2007. At
the same time, the use in other Dutch hospitals further in-
creased (6).
Although it is generally agreed upon that more antimicrobial
use results in an increase in the rate of resistance, it is unclear
if the opposite is also true. We measured the susceptibility of
E. coli, since this organism is an important target for quino-
lones and is the most frequently encountered clinically relevant
species of the Enterobacteriaceae family. Before the start of the
interventions, the observed rate of resistance to CIP increased
4.6% annually (Fig. 4). This increase was interrupted by a
stepwise decrease in the rate of resistance, and this was most
likely associated with interventions 2 and 4. The data showed
that at least one intervention was associated with a reduction in
the rate of resistance, but there was no conclusive evidence to
determine which intervention.
There are several difficulties in determining the association
of the interventions with the observed resistance. The relation-
ship between the amount of antimicrobial use and the devel-
opment of resistance has been clearly established both in the
community setting (9, 15, 23, 25) and in the hospital setting (11,
31). However, the extent to which a trend toward increasing
rates of resistance can be reversed by changes in prescribing
practices is less clear. For example, the complete cessation of
sulfonamide use in the United Kingdom did not lead to a
decrease in the rate of resistance in E. coli during the 1990s (7).
A likely explanation is that plasmids containing sulfonamide
resistance determinants also contained genes encoding resis-
tance to other antibiotics and that continued use of these
agents during the study period maintained the selective pres-
sure for the multiresistance plasmids (7, 13). Lipsitch con-
cluded that interventions to control antimicrobial use could
decrease the rate of resistance, but expectations for their suc-
cess should be moderate, as the relations are indirect and
nonlinear (13). He postulated that in the most successful cases
in the community, 5 years or more is required to observe a
substantial decline in the rate of resistance (13). Van Eldere et
al. also reported that changes in the observed rates of resis-
tance among Streptococcus pneumoniae isolates was delayed
after the level of use of broad-spectrum penicillins decreased
(28). Of note, that study described a reservoir of resistance in
the community which was probably different from that in the
hospital setting. In our hospital-based study, the change in the
resistance rate occurred approximately 6 months after the level
of CIP use was reduced. In contrast to the community, changes
in antimicrobial prescribing practices in hospitals could have a
much more rapid effect, because of the dilution effect of the
newly admitted patients (14). This hypothesis is based on the
TABLE 3. Segmented Poisson regression results for the ciprofloxacin resistance dataa
Intervention or
parameter
Model averaged
coefficientb (SD)
Probability of
an intervention
effectc
Full model Model 1 Model 2 Model 3
IRRd
(95% CI) P
IRR
(95% CI) P
IRR
(95% CI) P
IRR
(95% CI) P
Intervention 1 0.98 (0.08) 0.12 0.78 (0.16, 3.82) 0.76
Intervention 2 0.90 (0.16) 0.34 0.56 (0.22, 1.45) 0.23 0.71 (0.50, 1.00) 0.05
Intervention 3 0.77 (0.24) 0.52 0.48 (0.26, 0.89) 0.02 0.67 (0.53, 0.85) 0.001
Intervention 4 0.71 (0.24) 0.61 0.57 (0.20, 1.60) 0.29 0.52 (0.40, 0.68) 0.001 0.49 (0.38, 0.64) 0.001 0.67 (0.52, 0.85) 0.001
Trend prior to
intervention
1.04 (0.01)) 1 1.05 (1.03, 1.07) 0.001 1.05 (1.03, 1.06) 0.001 1.04 (1.03, 1.05) 0.001 1.04 (1.03, 1.05) 0.001
Change in trend after
intervention:
1 0.99 (0.02) 0.19 1.04 (0.68, 1.58) 0.85
2 1.00 (0.02) 0.13 1.05 (0.69, 1.60) 0.82
3 0.99 (0.07) 0.15 1.10 (0.53, 2.31) 0.80
4 1.02 (0.07) 0.15 0.83 (0.41, 1.67) 0.60
a The results of the model-averaged estimates, full model, and three best-fitting models selected by BMA are shown. Confidence intervals are calculated by
bootstrapping. The posterior model probabilities were 0.01, 0.11, 0.09, and 0.07 for the full model and models 1 to 3, respectively.
b Expected value of coefficient obtained by Bayesian model averaging, combining results from multiple models, weighted according to model probability (see
Materials and Methods).
c The probability that the coefficient is not zero in the Bayesian model averaging results.
d IRR, incidence rate ratio.
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assumption that cross infection with resistant strains is minimal
and that resistance rates among outpatients are lower than
those among hospitalized patients. Recent studies in our hos-
pital found a low rate of nosocomial transmission of highly
resistant Gram-negative bacteria. The number of infections
due to a strain and acquired by nosocomial transmission di-
vided by the number of infections due to strains of the same
species and not acquired by nosocomial transmission was 0.05
(32). The resistance rate for CIP in the community in the
Netherlands is also relatively low. A recent study reported 3%
CIP resistance among bacterial pathogens isolated from pa-
tients on admission to the hospital (2). Moreover, we previ-
ously demonstrated that the rate of CIP resistance on individ-
ual medical wards correlated with the amount of use on the
individual wards (31). These data suggest that the volume of
antimicrobial use in the hospital is an important determinant
for the observed resistance. Our study design prevents us
from making strong statements about what caused the de-
crease in the CIP resistance rate. We can conclude that it is
at least plausible that the decreased incidence of CIP-resis-
tant E. coli isolates cultured from clinical patients in our
hospital resulted from changes in the levels of quinolone
use.
There are some limitations of this study. First, we used a
quasiexperimental interrupted time series design, which has
well-known limitations (21). We were able to overcome some
of these through use of a segmented regression analysis, the
most appropriate method for assessing the effects of our inter-
ventions on reducing the levels of use of CIP and other anti-
microbial agents. However, it is less clear how we should an-
alyze and interpret the subsequent effects on the observed
resistance, given the uncertainties about the mechanisms se-
lected for the resistant organisms (13, 14). Second, the ICU
was excluded from the study. We did not include that unit
because the consultant microbiologists involved in the study
visited the ICU on a daily basis to advise physicians about
antimicrobial treatment. Therefore, we assumed that we would
not be able to improve antimicrobial use in that unit. Third, the
follow-up period was relatively short, which prevented us from
determining the long-term effect of this intervention on anti-
microbial resistance.
The observed effect on the CIP resistance rates could also be
biased by the occurrence of outbreaks or by changes in the
infection control policy that were not part of the bundle of
interventions. As mentioned before, we measured the occur-
rence of the horizontal spread of resistant microorganisms in
the hospital during the study period and found a very low rate
of transmission, and no major outbreaks were observed (32).
The infection control policy regarding the prevention of trans-
mission of resistant microorganisms was implemented before
2005, and no changes have been made since then. Therefore, it
is unlikely that the observed resistance rates were influenced
by these factors.
The cost analysis was limited to the cost of the change from
i.v. to oral CIP use. This was a very clear intervention with no
hidden costs or substitution effects. The effects of the reduced
total level of use of CIP were not included in the cost analysis.
Although there are likely cost savings associated with this as
well, these are much more difficult to quantify. The total
amount of antibiotic use did not increase, and no new, more
expensive agents were used during the study period. Therefore,
the savings calculated for this report are a minimal estimate.
Still, this minimal estimate was sufficient to pay for the costs of
this project.
In conclusion, multiple targeted interventions improved the
use of CIP in our hospital. A Switch project from i.v. to oral
therapy was successful and saved money. Subsequent interven-
tions, including the introduction of a new guideline and an
educational program, reduced the overall level of CIP use by
30%. An increasing trend in the rates of resistance observed
among the E. coli isolates was reversed in association with the
decrease in the level of CIP use. These findings show that a
bundle of interventions can reduce the levels of use of antimi-
crobial agents in a hospital and could reverse the increase in
the rate of antimicrobial resistance.
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